Gilead small molecule demonstrates strong capability for HIV prevention
According to Gilead, the study is the first Phase III HIV prevention trial to demonstrate a zero-infection rate.
List view / Grid view
According to Gilead, the study is the first Phase III HIV prevention trial to demonstrate a zero-infection rate.
With two knighthoods in the last month, here EPR discusses five developments in the drug development community’s C-suite.
The companies have agreed to jointly develop and commercialise long-acting, investigational treatment combinations of lenacapavir and islatravir for HIV.